Epsilogen Ltd.
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Holding
- Established
- 2016-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.epsilogen.com
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)A Study of MOv18 IgE in Folate Receptor Alpha-expressing Platinum Resistant Ovarian Cancer
Phase 1
Recruiting
- Conditions
- Advanced Ovarian CancerPlatinum-resistant Ovarian Cancer
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- Epsilogen Ltd
- Target Recruit Count
- 45
- Registration Number
- NCT06547840
- Locations
- 🇬🇧
Bristol Haematology and Oncology Centre, Bristol, United Kingdom
🇬🇧Edinburgh Cancer Research Centre, Edinburgh, United Kingdom
🇬🇧Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
News
Epsilogen Completes Series B Expansion to Advance IgE Antibody Therapy for Ovarian Cancer
Epsilogen secured additional funding of £12.5m in Series B expansion, bringing the total to £43.25m, to support clinical development of its IgE antibody pipeline.